Real World Outcomes with VTD and Cybord Induction Treatment for Transplant Eligible Multiple Myeloma Patients in a Latin American Country. Retrospective Cohort Study from Gamm (Grupo Argentino de Mieloma Multiple)

Real World Outcomes with VTD and Cybord Induction Treatment for Transplant Eligible Multiple Myeloma Patients in a Latin American Country. Retrospective Cohort Study from Gamm (Grupo Argentino de Mieloma Multiple)

Authors:

Natalia Paola Schutz, MD MSc, Paola Ochoa, MD, Patricio Duarte, MD, Guillermina Remaggi, MD, Sebastian Yantorno, MD, Ariel Corzo, MD, Soledad Zabaljauregui, MD, Claudia Shanley, MD, Sergio Lopresti, MD, Sergio Orlando, MD, Veronica Verri, MD, Luis Dario Quiroga, MD, Carlos García, MD, Vanesa Fernandez, MD, Dorotea Beatriz Fantl, MD

Abstract:

There are scarce data regarding treatment outcomes and toxicity in Latin American countries. Argentina is the second largest country in the region and the fourth most populated one. National Guidelines from the Argentinean Society of Hematology (SAH) recommends the use of bortezomib based triplets for induction treatment in transplant eligible newly diagnosed Multiple Myeloma patients.

Publication:

Blood (2018) 132 (Supplement 1): 3301. https://doi.org/10.1182/blood-2018-99-116243

 

 

 

 

Significant Differences in Test Availability and Access to Novel Drugs for Multiple Myeloma between Public and Private Hospitals in Latin America. Grupo De Estudio Latinoamericano De Mieloma Multiple (GELAMM)

Blood (2018) 132 (Supplement 1): 2244. https://doi.org/10.1182/blood-2018-99-111429

Authors:

Eloisa Riva, MD, Natalia Paola Schutz, MD, Camila Peña, MD, Fiorella Villano, MD, Guillermo J. Ruiz-Argüelles, FRCP, MACP, Juan Ramon Navarro, MD, Willem Bujan, MD, Lidiane Andino Neves, MD, Christine Rojas, MD, Hernán López-Vidal, MD, Angelina Rodriguez, MD, Virginia Bove, MD, Miguel Rodriguez, MD, Dorotea Beatriz Fantl, MD

Abstract:

Compliance with Multiple Myeloma (MM) recommendations regarding diagnosis and treatment is highly variable worldwide, outside clinical trials. This survey among hematologists from Latin America (LA) aims to describe real access to diagnostic and prognostic analyses and first line treatment for newly diagnosed MM (NDMM).

Epidemiological and Clinical Characteristics of Monoclonal Gammopathy of Renal Significance (MGRS) in South America

Blood (2018) 132 (Supplement 1): 5856. https://doi.org/10.1182/blood-2018-99-113198

Authors:

Camila Peña, MD, Gonzalo P Mendez, MD, Natalia Paola Schutz, MD, Eloisa Riva, MD, Ricardo Valjalo, MD, Hernán López-Vidal, MD, Alejandro Majlis, MD, Vivianne Lois, MD, Daniela Zamora, MD, Jose T Gonzalez, MD, Dorotea Beatriz Fantl, MD

Abstract:

Monoclonal gammopathy of renal significance (MGRS) is a recently defined entity. It is a group of renal diseases due to paraprotein deposition from a small B lymphocyte or plasma cell clon, not meeting the criteria for an overt gammopathy-associated neoplasm. Despite this feature, the secondary kidney damage may be severe and irreversible; therefore, its early recognition and treatment are crucial. There are few studies on MGRS in the international literature, and no reported data from Latin America (LA).